| Intended Result | | Your Report | Your Score |
|---|---|---|---|
| Specimen 8318 | HPV high risk genotype(s) detected | HPV high risk genotype(s) detected | 2 |
| Specimen 8319 | HPV high risk genotype(s) detected | HPV high risk genotype(s) detected | 2 |
| Specimen 8320 | HPV high risk genotype(s) not detected | HPV high risk genotype(s) not detected | 2 |
| Specimen 8321 | HPV high risk genotype(s) detected | HPV high risk genotype(s) detected | 2 |

**Cumulative score information**
Total number of specimens sent to you for **UK NEQAS for Molecular detection of HPV** over the last 3 distributions is 12
For these distributions specimen numbers 7926 7927 7928 7929 8115 8116 8117 8118 8318 8319 8320 8321 have been analysed and scored.
Number of reports analysed 12
Number of specimens reported as not examined (not scored) 0
Number of specimens received too late for analysis (not scored) 0
Number of specimens for which no report was received (not scored) 0
Your cumulative score for these specimens was 24 out of a possible total of 24
The mean score calculated from the reports returned by **UK** laboratories was 23.88 with a standard error of 1.10.

**Performance rating**
Your performance rating for **UK NEQAS for Molecular detection of HPV** (i.e. the number of standard errors by which your cumulative score lies above or below the mean) for **UK** laboratories is **0.11.**
A performance rating of more than 1.96 standard errors below the mean indicates possible poor performance.
Please note your performance rating may alter if other participants' results are amended.
No score penalty is incurred for non return of reports. However non return of results may be used as a measure of poor performance.







**Comments:**

A total of 128 sets of specimens were distributed with 118 participants returning results within the specified period.

**Specimen 8318** consisted of pooled clinical cervical samples positive for HPV high risk genotype 16, low risk genotypes 42 and 44, and genotypes 53 and 66. 99.1% of participants correctly reported the presence of high risk HPV genotype(s).
**Specimen 8319** consisted of pooled clinical cervical samples positive for HPV high risk genotypes 31, 33, 39, 56 and 58, low risk genotypes 6 and 61, and genotypes 53, 70 and 82. 99.1% of participants correctly reported the presence of high risk HPV genotype(s).
**Specimen 8320** consisted of the HPV negative C33a cell line. 99.1% of participants correctly reported that high risk HPV genotypes were not detected in this specimen.
**Specimen 8321** consisted of the high risk HPV 18 positive HeLa cell line. 97.4% of participants correctly reported the presence of high risk HPV genotype(s).
**Please see page 6 for comments.**

In the histograms on page 2 and subsequent pages a maximum of 12 kit results are displayed: these include the most commonly used methods and the method(s) used in your laboratory indicated by an arrow(s). The figures in the histograms and those in the overall results tables may differ:
(1) due to exclusion of kits displayed in the histograms resulting in apparently lower numbers of data sets in the histograms or
(2) due to participants using more than one kit resulting in higher numbers of data sets in the histograms.

**Turn around time:** The time taken to report your results was 2-days. This information is provided for your own use and does not form part of your performance assessment.

**Acknowledgements:** We thank colleagues from the Scottish HPV Reference Laboratory, the Scottish HPV Archive, the Queen's Medical Research Institute of the University of Edinburgh, and the Virus reference department of UKHSA for pre-distribution testing.

**Enquiries:** Pre-distribution test results are available should you experience a technical failure and wish to discuss the results. Written enquiries about this distribution should be addressed to Dr Sanjiv Rughooputh at organiser@ukneqasmicro.org.uk. For repeat specimens in case of an EQA failure, please request using the web form at **https://ukneqasmicro.org.uk/participant-info/order-repeat-specimens/.**

**Report authorised by:** Dr Sanjiv Rughooputh, Scheme Organiser.

Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ


UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:40 on Wednesday 27 March 2024

Four cervical and simulated cervical specimens in liquid based cytology fluid (PreservCyt) were dispatched with the request to report on the detection of papillomaviruses by molecular methods. Specimens 8318 and 8319 were prepared from pooled clinical samples positive for HPV high risk genotypes 16 and 31, 33, 39, 56 and 58, respectively. Specimen 8320 consisted of the diluted HPV negative C33a cell line. Specimen 8321 consisted of the diluted HeLa cell line positive for high risk HPV 18.

## Specimen : 8318

**HPV high risk genotype(s) detected**




| | UK | (%) | All | (%) |
|---|---|---|---|---|
| PCR: Multiplex | 2 | (4.8) | 3 | (1.9) |
| Cepheid: GeneXpert | 7 | (16.7) | 18 | (11.5) |
| Hologic: Aptima | 14 | (33.3) | 19 | (12.1) |
| Fujirebio : INNO-LiPA | 0 | (0.0) | 4 | (2.5) |
| Seegene: Anyplex II HPV HR | 0 | (0.0) | 7 | (4.5) |
| BD : Onclarity | 0 | (0.0) | 7 | (4.5) |
| Roche: Cobas 5800 | 0 | (0.0) | 8 | (5.1) |
| Abbott: Alinity m | 0 | (0.0) | 8 | (5.1) |
| Seegene: Allplex HPV28 | 2 | (4.8) | 10 | (6.4) |
| Seegene: Anyplex II HPV28 | 1 | (2.4) | 13 | (8.3) |
| Cobas 6800/8800 | 8 | (19.0) | 16 | (10.2) |
| Roche: Cobas 4800 | 6 | (14.3) | 18 | (11.5) |

Your Report : HPV high risk genotype(s) detected

Your Score : **2**

| Overall Results | UK | All | Score |
|---|---|---|---|
| Detected | 15 | 115 | 2 |
| Not detected | 0 | 1 | -1 |
| Total | 15 | 116 | |
| % Correct | 100 | 99.1 | |

## Specimen : 8318 HPV high risk genotype 16 detected

HPV high risk genotype combinations reported

| UK | (All) | |
|---|---|---|
| 12 | (81) | 16 |
| 2 | (8) | 16,31,33,35,39,45,51,52,56,58,59,68 |
| 0 | (1) | 16,31,33,35,39,51,52,56,58,59,68 |
| 0 | (1) | 16,35,39,51,56,59,68 |
| 1 | (2) | 16,39,56,68 |
| 0 | (1) | 16,45 |
| 0 | (4) | 16,56,59 |
| 0 | (1) | 18 |












UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:40 on Wednesday 27 March 2024

Four cervical and simulated cervical specimens in liquid based cytology fluid (PreservCyt) were dispatched with the request to report on the detection of papillomaviruses by molecular methods. Specimens 8318 and 8319 were prepared from pooled clinical samples positive for HPV high risk genotypes 16 and 31, 33, 39, 56 and 58, respectively. Specimen 8320 consisted of the diluted HPV negative C33a cell line. Specimen 8321 consisted of the diluted HeLa cell line positive for high risk HPV 18.

## Specimen : 8319

**HPV high risk genotype(s) detected**




| | UK | (%) | All | (%) |
|---|---|---|---|---|
| PCR: Multiplex | 2 | (4.8) | 3 | (1.9) |
| Cepheid: GeneXpert | 7 | (16.7) | 18 | (11.5) |
| Hologic: Aptima | 14 | (33.3) | 19 | (12.1) |
| Fujirebio : INNO-LiPA | 0 | (0.0) | 4 | (2.5) |
| Seegene: Anyplex II HPV HR | 0 | (0.0) | 7 | (4.5) |
| BD : Onclarity | 0 | (0.0) | 7 | (4.5) |
| Roche: Cobas 5800 | 0 | (0.0) | 8 | (5.1) |
| Abbott: Alinity m | 0 | (0.0) | 8 | (5.1) |
| Seegene: Allplex HPV28 | 2 | (4.8) | 10 | (6.4) |
| Seegene: Anyplex II HPV28 | 1 | (2.4) | 13 | (8.3) |
| Cobas 6800/8800 | 8 | (19.0) | 16 | (10.2) |
| Roche: Cobas 4800 | 6 | (14.3) | 18 | (11.5) |

Your Report : HPV high risk genotype(s) detected

Your Score : **2**

| Overall Results | UK | All | Score |
|---|---|---|---|
| Detected | 15 | 115 | 2 |
| Not detected | 0 | 1 | -1 |
| Total | 15 | 116 | |
| % Correct | 100 | 99.1 | |

## Specimen : 8319

**HPV high risk genotypes 31, 33, 39, 56 and 58 detected**

HPV high risk genotype combinations reported




| UK | (All) | |
|---|---|---|
| 0 | (1) | 16,31,33,35,39,51,52,56,58,59,68 |
| 0 | (1) | 18,45 |
| 0 | (2) | 31 |
| 2 | (8) | 31,33,35,39,45,51,52,56,58,59,68 |
| 1 | (5) | 31,33,35,39,51,52,56,58,59,68 |
| 0 | (3) | 31,33,35,39,56,58,59,68 |
| 0 | (2) | 31,33,39,45,56,58 |
| 0 | (3) | 31,33,39,45,56,58,59 |
| 0 | (1) | 31,33,39,51,56,58 |
| 3 | (20) | 31,33,39,56,58 |
| 0 | (7) | 31,33,39,56,58,59 |
| 0 | (1) | 31,33,39,58 |
| 0 | (1) | 31,33,39,58,59 |
| 0 | (1) | 31,33,56 |
| 0 | (5) | 31,33,56,58 |
| 1 | (2) | 31,33,56,58,59 |
| 0 | (2) | 31,33,58 |
| 0 | (1) | 31,333,35,39,45,56,58,59,68 |
| 0 | (2) | 31,58 |
| 0 | (1) | 58 |






UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:40 on Wednesday 27 March 2024

Four cervical and simulated cervical specimens in liquid based cytology fluid (PreservCyt) were dispatched with the request to report on the detection of papillomaviruses by molecular methods. Specimens 8318 and 8319 were prepared from pooled clinical samples positive for HPV high risk genotypes 16 and 31, 33, 39, 56 and 58, respectively. Specimen 8320 consisted of the diluted HPV negative C33a cell line. Specimen 8321 consisted of the diluted HeLa cell line positive for high risk HPV 18.

## Specimen : 8320

**HPV high risk genotype(s) not detected**




| | UK | (%) | All | (%) |
|---|---|---|---|---|
| PCR: Multiplex | 2 | (4.8) | 3 | (1.9) |
| Cepheid: GeneXpert | 7 | (16.7) | 18 | (11.5) |
| Hologic: Aptima | 14 | (33.3) | 19 | (12.1) |
| Fujirebio : INNO-LiPA | 0 | (0.0) | 4 | (2.5) |
| Seegene: Anyplex II HPV HR | 0 | (0.0) | 7 | (4.5) |
| BD : Onclarity | 0 | (0.0) | 7 | (4.5) |
| Roche: Cobas 5800 | 0 | (0.0) | 8 | (5.1) |
| Abbott: Alinity m | 0 | (0.0) | 8 | (5.1) |
| Seegene: Allplex HPV28 | 2 | (4.8) | 10 | (6.4) |
| Seegene: Anyplex II HPV28 | 1 | (2.4) | 13 | (8.3) |
| Cobas 6800/8800 | 8 | (19.0) | 16 | (10.2) |
| Roche: Cobas 4800 | 6 | (14.3) | 18 | (11.5) |

Your Report : HPV high risk genotype(s) not detected

Your Score : **2**

| Overall Results | UK | All | Score |
|---|---|---|---|
| Detected | 0 | 1 | -1 |
| Not detected | 15 | 115 | 2 |
| Total | 15 | 116 | |
| % Correct | 100 | 99.1 | |


Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ





UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH



Published at 10:40 on Wednesday 27 March 2024

Four cervical and simulated cervical specimens in liquid based cytology fluid (PreservCyt) were dispatched with the request to report on the detection of papillomaviruses by molecular methods. Specimens 8318 and 8319 were prepared from pooled clinical samples positive for HPV high risk genotypes 16 and 31, 33, 39, 56 and 58, respectively. Specimen 8320 consisted of the diluted HPV negative C33a cell line. Specimen 8321 consisted of the diluted HeLa cell line positive for high risk HPV 18.

## Specimen : 8321

**HPV high risk genotype(s) detected**




| | UK | (%) | All | (%) |
|---|---|---|---|---|
| PCR: Multiplex | 2 | (4.8) | 3 | (1.9) |
| Cepheid: GeneXpert | 7 | (16.7) | 18 | (11.5) |
| Hologic: Aptima | 14 | (33.3) | 19 | (12.1) |
| Fujirebio : INNO-LiPA | 0 | (0.0) | 4 | (2.5) |
| Seegene: Anyplex II HPV HR | 0 | (0.0) | 7 | (4.5) |
| BD : Onclarity | 0 | (0.0) | 7 | (4.5) |
| Roche: Cobas 5800 | 0 | (0.0) | 8 | (5.1) |
| Abbott: Alinity m | 0 | (0.0) | 8 | (5.1) |
| Seegene: Allplex HPV28 | 2 | (4.8) | 10 | (6.4) |
| Seegene: Anyplex II HPV28 | 1 | (2.4) | 13 | (8.3) |
| Cobas 6800/8800 | 8 | (19.0) | 16 | (10.2) |
| Roche: Cobas 4800 | 6 | (14.3) | 18 | (11.5) |

Your Report : HPV high risk genotype(s) detected

Your Score : **2**

| Overall Results | UK | All | Score |
|---|---|---|---|
| Detected | 15 | 113 | 2 |
| Not detected | 0 | 3 | -1 |
| Total | 15 | 116 | |
| % Correct | 100 | 97.4 | |

## Specimen : 8321 HPV high risk genotype 18 detected

HPV high risk genotype combinations reported

| UK | (All) |
|---|---|
| 14 | (90) |
| 0 | (7) |
| 0 | (1) |








Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ





UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH



Published at 10:40 on Wednesday 27 March 2024

## Comments on distribution 5535

Overall performance in this distribution was very good with 98.7% of participants reporting the intended results for the 4 specimens.

This is a decline of 0.4% to the previous distribution 5472, where 99.1% of participants reported the intended results.

The return rate was very good with 92.2% of participants returning results within the specified time. This is an improvement of 0.9% on the previous distribution 5472, where 91.3% of participants returned their results.

### Investigating incorrect results and non-return of results

Participants who did not obtain the intended results are requested to investigate and report the plausible root cause by completing an incident review form (IRF) online within 30 days of this report being published. IRFs are taken into considerations when poor performance analysis is carried out for the National Quality Assurance Advisory Panel (NQAAP).

**Non-return of results is considered as poor performance.**

Participants who did not return their results should also complete an IRF. IRFs are available on the following link: https://uknegasmicro.org.uk/incident-review-form/

**End of report**





UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:40 on Wednesday 27 March 2024